Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BYON3521 dose-escalation and expansion study in c-MET-expressing advanced solid tumors
NL-OMON56017Phase 1Recruiting
- Sponsor
- Fortrea
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BYON3521 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), ovarian cancer and 5 more (5 arms), sponsored by Fortrea. Primary endpoints: Dose-limiting toxicities and Objective response rate. Started Jul 2022; status: recruiting.
02
Drugs
BYON3521
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON56017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56017.